Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Straumann Holding AGMEX:STMN N 95 EV-to-EBITDA is 23.40 as of Jul. 22, 2026, which is 25% below its 10-year median of 31.03. GuruFocus rates MEX:STMN N with a GF Score™ of 95/100 and a GF Value™ of MXN3,574.98. The stock has 5 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 75.1% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Straumann Holding AG's enterprise value is MXN338,686 Mil.
Straumann Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was MXN14,471 Mil. Therefore, Straumann Holding AG's EV-to-EBITDA for today is 23.40.
The historical rank and industry rank for Straumann Holding AG's EV-to-EBITDA or its related term are showing as below:
MEX:STMN N'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 19.15 Med: 31.03 Max: 142.97
Current: 24.9
During the past 13 years, the highest EV-to-EBITDA of Straumann Holding AG was 142.97. The lowest was 19.15. And the median was 31.03.
MEX:STMN N's EV-to-EBITDA is ranked worse than 75.1% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.93
vs MEX:STMN N: 24.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Straumann Holding AG (MEX:STMN N) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Straumann Holding AG's PE Ratio (TTM) for today is calculated as:
Straumann Holding AG's share price for today is MXN2577.02.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Straumann Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was MXN51.623.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Straumann Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:STMN N vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's EV-to-EBITDA falls into.
Straumann Holding AG's current Enterprise Value is MXN338,686 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Straumann Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was MXN14,471 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG (MEX:STMN N) has a EV-to-EBITDA of 23.40 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Straumann Holding AG. This is 25% below median its historical median of 31.03. Over the past decade, Straumann Holding AG's EV-to-EBITDA has ranged from 19.15 to 142.97. According to the industry distribution chart, Straumann Holding AG ranks #383 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 75.1%.
Is Straumann Holding AG's EV-to-EBITDA too high?
Straumann Holding AG's current EV-to-EBITDA of 23.40 is 25% below median its 10-year median of 31.03. Over the past 10 years, this metric has ranged from a low of 19.15 to a high of 142.97. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.93. Straumann Holding AG's value of 23.40 is 68% above this industry median. Based on the distribution chart, Straumann Holding AG ranks #383 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Straumann Holding AG has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #383 out of 510 companies for EV-to-EBITDA. This places Straumann Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 13.93. Straumann Holding AG's value of 23.40 is 68% above this benchmark. Historically, Straumann Holding AG's own EV-to-EBITDA has ranged from 19.15 to 142.97 over the past decade. While the company's 10-year median is 31.03 vs. the industry median of 13.93, Straumann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.93, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current EV-to-EBITDA of 23.40 is 68% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Straumann Holding AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current EV-to-EBITDA is 23.40, which is 25% below median its own 10-year median of 31.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Straumann Holding AG (MEX:STMN N) has a current EV-to-EBITDA of 23.40. The stock's GF Value™ is MXN3,574.98, compared to a current price of MXN2,577.02 — trading 27.9% below its estimated fair value. The current EV-to-EBITDA is 23.40, which is 25% below median its 10-year median of 31.03 and 68% above the Medical Devices & Instruments industry median of 13.93. Straumann Holding AG's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Straumann Holding AG (MEX:STMN N), the current EV-to-EBITDA is 23.40 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (MEX:STMN N) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of MXN2,577.02 is trading 27.9% below its estimated GF Value™ of MXN3,574.98.
Key valuation signals for MEX:STMN N:
EV-to-EBITDA: 23.40 (25% below median its 10-year median of 31.03)
GF Value™: MXN3,574.98 vs. price of MXN2,577.02 (27.9% below fair value)
Industry Position: 68% above the Medical Devices & Instruments median (#383 of 510)
No single metric tells the full story. See the MEX:STMN N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
95GF Score
Get the complete analysis for MEX:STMN N
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:STMN N has been successfully added to your 
